Eligo Bioscience is a startup based in France, most recent round Series B, 1 tracked investor.
Eligo Bioscience is a startup founded in 2014 based in France. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
Eligo Bioscience develops programmable biotherapeutic nanobots that target specific bacteria in the human microbiome to treat diseases such as inflammatory bowel disease, colorectal cancer, and acne.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.